Abstract
At present, there is no means of predicting the response of an individual patient to a given drug, invariably some patients will respond whereas others will fail and many will experience adverse drug reactions. Recent advances in chemotherapy have introduced a battery of receptor tyrosine kinase and mTOR inhibitors targeting renal cell carcinoma (RCC). In this experiment, we apply a new in vivo model of \#8220;tailor-made chemotherapy\#8221; to determine an individual\#8217;s tumor response to multiple chemotherapeutic treatments to predict the right treatment option. We compared the treatment response form fresh surgically resected clear cell carcinoma transplanted into nude mice treated with bevacizumab (5 mg/kg i.p.) or RAD001 (5 mg/kg i.p. twice/week). We determined treatment efficacy by measuring tumor growth, morphology, angiogenesis and expression of associated signaling pathway markers by histology and immunohistochemistry. Treatment responses to bevacizumab or RAD001 based on tumor volumes are summarized below:$$table_{E0EECD69-52EC-47A7-8784-69EC2C674228}$$ Tumor response to bevacizumab coincided with tumor over expression of VEGFR-2 marked by decreased post-treatment microvessel density counts. Decreased p-MTOR and p-S6K levels characterized tumors responding to RAD001. Further experiments to evaluate more treatment options need to be conducted to validate its utility in the clinical setting.
Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 2341.
100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO
RSS Feeds